New research data reflect patient satisfaction following faricimab treat-and-extend regimen

News
Article

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

A patient covers her eye to perform a Snellen chart test as the optometrist looks on. Image credit: ©megaflopp – stock.adobe.com

Study results showed that the best-corrected visual acuity was maintained 6 months after the patients were switched to the faricimab treat-and-extend regimen Image credit: ©megaflopp – stock.adobe.com

A Japanese study found that switching to faricimab (Vabysmo, Genentech) treatment using a treat-and-extend (TAE) regimen seems to maintain the best-corrected visual acuity (BCVA) and extend the injection interval in patients with neovascular age-related macular degeneration (nAMD), resulting in enhanced satisfaction 6 months after patients were switched.1 Taiichi Hikichi, MD, who is in private practice in Sapporo, Japan, reported his findings in the Japanese Journal of Ophthalmology.

Dr Hikichi conducted a retrospective observational study of 48 consecutive eyes of 48 patients with nAMD who were switched to faricimab and followed for 6 months while they were on a TAE regimen. At the 6-month time point, the patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ).

The results showed that the BCVA was maintained 6 months after the patients were switched to the faricimab TAE regimen. In addition, the mean central foveal thickness decreased significantly (p < 0.001) at 6 months compared to the time at which patients started on faricimab from 372 ± 20 μm to 272 ± 14 μm.

The treatment interval following the switch was 10.45 ± 0.44 weeks, which differed significantly (p = 0.002) from the treatment interval of 6.72 ± 0.34 weeks at the time of the switch.

Dr Hikichi also reported that the MacTSQ total score of 58.8 ± 1.7 in eyes with a BCVA of 20/40 and better 6 months after the switch was significantly (p < 0.001). higher compared to that in eyes with a BCVA worse than 20/40 (48.2 ± 1.5). The MacTSQ total score of 56.8 ± 1.8 in eyes in which a 4-week extension of the injection interval was achieved was significantly higher than the 49.5 ± 1.9 in eyes without (p < 0.001).

He concluded that switching to faricimab administered using a TAE regimen seems to maintain the BCVA and extend the injection interval in patients with nAMD, resulting in enhanced patient satisfaction.

Reference

1. Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652-6; https://doi.org/10.1007/s10384-023-01024-4

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.